These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11796385)

  • 1. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation.
    Drusano GL; Preston SL; Gotfried MH; Danziger LH; Rodvold KA
    Antimicrob Agents Chemother; 2002 Feb; 46(2):586-9. PubMed ID: 11796385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin.
    Drusano GL; Preston SL; Van Guilder M; North D; Gombert M; Oefelein M; Boccumini L; Weisinger B; Corrado M; Kahn J
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2046-51. PubMed ID: 10898674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation.
    Lodise TP; Gotfried M; Barriere S; Drusano GL
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2300-4. PubMed ID: 18426898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects.
    Gotfried MH; Danziger LH; Rodvold KA
    Chest; 2001 Apr; 119(4):1114-22. PubMed ID: 11296178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
    Noreddin AM; Marras TK; Sanders K; Chan CK; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
    Rubino CM; Ma L; Bhavnani SM; Korth-Bradley J; Speth J; Ellis-Grosse E; Rodvold KR; Ambrose PG; Drusano GL
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4085-9. PubMed ID: 17846139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae.
    Ambrose PG; Grasela DM
    Diagn Microbiol Infect Dis; 2000 Nov; 38(3):151-7. PubMed ID: 11109013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients.
    Sánchez Navarro A; Colino Gandarillas CI; Alvarez Lerma F; Menacho YA; Domínguez-Gil A
    Clin Pharmacokinet; 2005; 44(6):627-35. PubMed ID: 15910010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid.
    Child J; Mortiboy D; Andrews JM; Chow AT; Wise R
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2749-51. PubMed ID: 8593013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
    Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Wong FA; Corrado M
    Antimicrob Agents Chemother; 1998 May; 42(5):1098-104. PubMed ID: 9593134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae.
    Nicolau DP; Ambrose PG
    Am J Med; 2001 Dec; 111 Suppl 9A():13S-18S; discussion 36S-38S. PubMed ID: 11755438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients.
    Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2015 May; 45(5):512-8. PubMed ID: 25726443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets.
    Louie A; Fregeau C; Liu W; Kulawy R; Drusano GL
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3325-30. PubMed ID: 19364849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.
    Chien SC; Wong FA; Fowler CL; Callery-D'Amico SV; Williams RR; Nayak R; Chow AT
    Antimicrob Agents Chemother; 1998 Apr; 42(4):885-8. PubMed ID: 9559801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
    Lodise TP; Kinzig-Schippers M; Drusano GL; Loos U; Vogel F; Bulitta J; Hinder M; Sörgel F
    Antimicrob Agents Chemother; 2008 Jun; 52(6):1945-51. PubMed ID: 17485507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis.
    Nicolau DP; Sutherland C; Winget D; Baughman RP
    Pulm Pharmacol Ther; 2012 Feb; 25(1):94-8. PubMed ID: 22210007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa.
    Deguchi T; Seike K; Yasuda M; Matsumoto T
    J Infect Chemother; 2011 Oct; 17(5):726-30. PubMed ID: 21409530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.
    Chien SC; Chow AT; Rogge MC; Williams RR; Hendrix CW
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1765-9. PubMed ID: 9257757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Penetration of levofloxacin into skin tissue after oral administration of multiple 750 mg once-daily doses.
    Chow AT; Chen A; Lattime H; Morgan N; Wong F; Fowler C; Williams RR
    J Clin Pharm Ther; 2002 Apr; 27(2):143-50. PubMed ID: 11975700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis.
    Zeitlinger MA; Dehghanyar P; Mayer BX; Schenk BS; Neckel U; Heinz G; Georgopoulos A; Müller M; Joukhadar C
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3548-53. PubMed ID: 14576116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.